Back
to sessions
Sep 29
Scientific
MODERATOR(S)
Salma Jabbour, MD, FASTRO - Rutgers Cancer Institute
Thomas DiPetrillo, MD - Brown University
Credits
| AMA PRA Category 1 Credits: | 1.25 |
| CAMPEP Credits: | 1.25 |
| MDCB Credits: | 1.25 |
Presentations
-
12:30pm - 12:40pm ET
A Prospective, Randomized Controlled Study on the Time Window of Radiotherapy Combined with Targeted Therapy for Primary Tumor in Stage IV NSCLC
Speaker: Feng Jin, BS - Affiliated Hospital of Guizhou Medical University, Guiyang -
12:40pm - 12:50pm ET
Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial
Speaker: Xiaoli Zheng, MD - The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Beijing -
12:50pm - 01:00pm ETSpeaker: Nitin Ohri, MD, MS - Albert Einstein College of Medicine, Bronx
-
01:00pm - 01:10pm ET
Pirfenidone for Reducing Radiation-Induced Lung Injury in Lung Cancer Patients with Prior Receipt of Immune Checkpoint Inhibitors: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial
Speaker: Chi Lin, MD, PhD, MS - University of Nebraska Medical Center, Omaha -
01:10pm - 01:20pm ET
Alteration Subtype is Prognostic of Intracranial Outcome and Predicts the Benefit of Upfront SRS in EGFR-Mutant NSCLC Brain Metastasis
Speaker: Emily Wo, PharmD - Robert Wood Johnson Medical School, New Brunswick -
01:20pm - 01:30pm ET
Combined Stereotactic Radiotherapy and Immunotherapy Improves Survival in Driver-Gene-Negative NSCLC Patients with Brain Oligometastases: A Phase II Observational Clinical Study
Speaker: Xiaomei Gong, MD, PhD - ShangHai pulmonary hospital, ShangHai -
01:30pm - 01:35pm ET
Feasibility of Aumolertinib followed by SRT in EGFR+ NSCLC Patients with Intracranial Oligo-Progression: A Phase II, Prospective Study
Speaker: Huiting Li, MD - Fudan University Shanghai Cancer Center, Shanghai